EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...

Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive ...

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...

(Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply KEYTRUDA QLEX™ ...

The trial failure reinforces Keytruda’s competitive position in first-line metastatic melanoma, where it already outperformed ...

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary ...

Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...

Regeneron (REGN) stock is in focus as the firm fails in a late-stage trial testing a combination therapy involving its ...